Will Bupa Arabia or other major Saudi insurers cover Itovebi?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Itovebi is on their formulary even if not currently stocked; others assess based on step-therapy criteria and biomarker documentation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you, your physician, or your hospital. We do not promise coverage from any payer.

Is Itovebi registered locally in Saudi Arabia?

Local registration status changes as Genentech/Roche pursues regional rollout; even where the drug is registered, the specific indication, presentation, or dosing strength your prescriber has written may not align with what is currently stocked. The SFDA named-patient pathway exists precisely to bridge these gaps for individually identified patients.

What about competitor therapies?

The treatment landscape includes alpelisib (the older PI3K-alpha inhibitor with more hyperglycaemia), capivasertib (AKT inhibitor in the same AKT/PI3K pathway), elacestrant in ESR1-mutated disease, and the CDK4/6 inhibitor class as backbone. The choice depends on the patient's full clinical profile and prescriber judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not steer prescribing decisions and we do not have a financial relationship with any specific manufacturer.

How is the cold chain or storage managed?

Itovebi ships in validated thermal packaging with continuous temperature logging through the lane. The cold-chain handoff or temperature-controlled handoff ends at the dispensing pharmacy; home storage instructions, where the patient takes the medicine home for self-administration, are part of the patient onboarding kit.

Do US manufacturer patient assistance programmes (such as Genentech/Roche co-pay or PAP programmes) extend to Saudi Arabia patients?

No. US-resident patient assistance programmes are limited to US-resident patients with US prescription coverage by programme design. Cross-border patients pay cash for the drug and the coordination fee, with local payer reimbursement assessed separately.

Indicative drug-only band: USD 14,500 to 17,000 per month. Delivered quote within 24h.Get my quote

Itovebi access in Saudi Arabia: the SFDA named-patient pathway

How Saudi Arabia patients legally obtain Itovebi (inavolisib) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

Quick orientation

Itovebi (inavolisib) is PI3K-alpha selective inhibitor and degrader approved by the US FDA in October 2024 for endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in combination with palbociclib and fulvestrant, in patients with disease recurrence on or within 12 months of completing adjuvant endocrine therapy. The drug is manufactured by Genentech/Roche. Saudi Arabia patients use the Saudi Food and Drug Authority named-patient pathway when the locally registered indication, the stocked presentation, or the available payer coverage does not match what the prescribing physician has written. Reserve Meds coordinates the US-side sourcing through a DSCSA-compliant specialty channel, builds the documentation packet your physician needs to file, and orchestrates the logistics into Saudi Arabia with a single named coordinator carrying the case end-to-end.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Itovebi reaches patients in Saudi Arabia

Itovebi (inavolisib, an oral PI3K-alpha-isoform-specific inhibitor with degradation activity against mutant PI3K-alpha, FDA-approved October 2024 in combination with palbociclib and fulvestrant for endocrine-resistant PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer following recurrence on or after completing adjuvant endocrine therapy; marketed by Genentech, a member of the Roche Group) is not currently visible on the SFDA registered-drug list at sfda.gov.sa/en/drugs-list as of 2026-05-31. Saudi residents access Itovebi through Personal Importation of Medicines (SFDA Clearance Permit for Personal Use) under SFDA Document Drug-6567E at sfda.gov.sa Drug-6567E PDF, or via the SFDA Special Access Programme (Pathway B) for institutional access. The Itovebi-specific clinical justification must document: confirmed PIK3CA mutation status (the FDA label requires a companion-diagnostic-detected PIK3CA mutation by FoundationOne CDx tissue or liquid biopsy), HR-positive HER2-negative breast cancer with recurrence on or after adjuvant endocrine therapy, the intended triple combination with palbociclib and fulvestrant, and the prescribing oncologist's licensure. Baseline fasting glucose and HbA1c per the FDA label (hyperglycaemia is a class effect of PI3K-alpha inhibitors) are referenced in the supporting medical report. The report must be dated within 6 months of submission.

Where Itovebi is dispensed in Saudi Arabia

Itovebi is an oral combination-regimen breast-oncology therapy; the dispensing setting is breast-oncology-experienced medical oncology with capacity for PIK3CA companion-diagnostic testing and ongoing fasting-glucose and HbA1c surveillance. Saudi tertiary oncology nodes include King Faisal Specialist Hospital and Research Centre (KFSHRC) Department of Medical Oncology and Comprehensive Cancer Center in Riyadh and Jeddah at kfshrc.edu.sa, which runs structured breast-oncology services and has institutional capacity for PIK3CA companion-diagnostic testing; King Fahad Medical City (KFMC) Comprehensive Cancer Center Breast Oncology in Riyadh at kfmc.med.sa; King Abdulaziz Medical City (KAMC) Princess Noorah Oncology Center Breast Oncology in Riyadh and Jeddah; Prince Sultan Military Medical City Oncology in Riyadh; King Fahad Specialist Hospital Dammam Oncology; and King Abdulaziz University Hospital Department of Oncology in Jeddah. KFSHRC is the most-likely dispensing node nationally for Itovebi given the institutional capacity for the FoundationOne CDx companion diagnostic and the structured breast-oncology service. The clinical workflow co-manages the PI3K-alpha-inhibitor-class hyperglycaemia risk with the same institution's endocrinology service.

What Itovebi costs in Saudi Arabia

The US reference WAC for Itovebi is approximately USD 19,000 to USD 21,000 per 30-day supply at the labelled dose (9 mg once daily) per Genentech disclosures and Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Annual Itovebi WAC at maintenance runs USD 225,000 to USD 250,000. The triple-combination regimen (Itovebi plus palbociclib plus fulvestrant) drives a combined US WAC in the USD 27,000 to USD 30,000 per month range when all three drugs are counted, depending on palbociclib generic availability. No public SAR benchmark for Itovebi is observed on the SFDA drugs list or via NUPCO at nupco.com as of 2026-05-31. Do not estimate. Price snapshot: 2026-05-31. The Saudi Riyal is USD-pegged at approximately 3.75 SAR per USD. Cost layers: ambient-temperature international logistics into Saudi Arabia (low to mid four-figure USD; Itovebi is a stable oral tablet), SFDA personal-import clearance fees (nominal), the dispensing hospital's breast-oncology consultation, PIK3CA companion-diagnostic testing if not already performed (FoundationOne CDx fee), fasting-glucose and HbA1c surveillance, and Reserve Meds concierge fee itemised separately.

Funding and access barriers for Itovebi in Saudi Arabia

HR-positive HER2-negative breast cancer is the most common breast-cancer subtype in Saudi tertiary practice; PIK3CA mutations occur in approximately 35 to 40% of HR-positive metastatic breast cancers, placing the Itovebi-eligible population at meaningful scale. The historical management of endocrine-resistant disease in this population spans CDK4/6 inhibitors plus endocrine therapy, alpelisib plus fulvestrant in PIK3CA-mutated cases, and other combinations; Itovebi is the second PI3K-alpha-class inhibitor (after alpelisib) but with a more selective profile. Public-sector funding: Saudi nationals receive specialty oncology care at MOH-affiliated centres without direct charge; NUPCO procurement covers registered breast-oncology drugs, but Itovebi is not currently on the NUPCO list. Institutional access via SFDA Special Access Programme is procedurally available with clinical committee approval based on documented PIK3CA mutation status and endocrine-therapy-resistant disease. The Council of Health Insurance Essential Benefits Package adjudicates the floor for cooperative-insurance coverage; major Saudi insurers (Bupa Arabia, Tawuniya, MedGulf, AXA Cooperative, Al Rajhi Takaful, Walaa Cooperative, SAICO) extend Itovebi coverage on higher-tier policies with prior authorisation and documented step-therapy. Roche Saudi Arabia operates a patient-support programme for selected oncology biologics; case-by-case Itovebi access support is at early-launch stage as of 2026-05-31. Out-of-pocket exposure is most material for expatriates outside the MOH-funded channel.

Recent regulatory and access news for Itovebi

FDA approved Itovebi (inavolisib) on 10 October 2024 based on the INAVO120 phase 3 trial demonstrating significant PFS improvement in the triplet combination versus palbociclib plus fulvestrant in PIK3CA-mutated HR+ HER2- endocrine-resistant metastatic breast cancer. The FDA approval letter is at accessdata.fda.gov/scripts/cder/daf. EMA (CHMP) issued a positive opinion for inavolisib in early 2025 with subsequent European Commission approval; the EMA EPAR is at ema.europa.eu/medicines/Itovebi. Roche has prioritised global launch including the Middle East. The SFDA News feed at sfda.gov.sa/en/news does not document an Itovebi-specific bulletin over the last 12 months as of 2026-05-31; SFDA submission timing has not been publicly disclosed by Roche Saudi Arabia.

Where Reserve Meds fits in Itovebi cases

Reserve Meds is a US-based concierge coordinator. We do not replace your Saudi specialist, we do not replace the SFDA, and we do not replace your dispensing pharmacy. For Itovebi specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate logistics into Saudi Arabia, and assign a single named coordinator through the case. The pharmacist-of-record review, prescription validation, biomarker confirmation, and physician sign-off are the recurring operational fundamentals for this drug.

Next step

If your Saudi physician has prescribed Itovebi and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Itovebi case Or message us on WhatsApp